fexofenadine has been researched along with Hay Fever in 79 studies
fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl
fexofenadine : A piperidine-based anti-histamine compound.
| Excerpt | Relevance | Reference |
|---|---|---|
| "fexofenadine is clinically effective in the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria for which it is a suitable option for first-line therapy." | 7.70 | Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. ( Jarvis, B; Simpson, K, 2000) |
| "The goal of the study was to determine if pranlukast has effects on the upper and lower airways through a comparison of the effects of fexofenadine and pranlukast on airway hyperresponsiveness in non-asthmatic patients with cedar pollinosis before the Japanese cedar pollen season and during the peak pollen season." | 5.14 | Effects of pranlukast hydrate on airway hyperresponsiveness in non-asthmatic patients with Japanese cedar pollinosis. ( Fukuda, T; Kashima, R; Okada, T; Sagara, H; Yukawa, T, 2009) |
| " However from 22 to 24 h after the first dose cetirizine was significantly superior to fexofenadine for the major symptom complex score and for sneezing." | 5.09 | Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. ( Burtin, B; De Vos, C; Donnelly, F; Horak, F; Kavina, A; Stübner, P; Zieglmayer, R, 2001) |
| "fexofenadine is clinically effective in the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria for which it is a suitable option for first-line therapy." | 3.70 | Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. ( Jarvis, B; Simpson, K, 2000) |
| "Cetirizine was similar." | 2.75 | The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. ( Horak, F; Lemell, P; Zieglmayer, P; Zieglmayer, R, 2010) |
| " Before the amendment, assessments included physical examination, vital signs reporting (oral temperature, heart rate, and respiratory rate), and adverse event (AE) reporting." | 2.73 | Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old. ( Hampel, FC; Kittner, B; Lanier, R; Milgrom, H, 2007) |
| " The absolute and percent change in TSC score and the percent change in MSC score were significantly decreased at all time points from 45 minutes after dosing for FEX60/PSE120 compared with placebo (all, P < 0." | 2.72 | Onset of action of fexofenadine hydrochloride 60 mg/pseudoephedrine hydrochloride 120 mg in subjects aged 12 years with moderate to severe seasonal allergic rhinitis: a pooled analysis of two single-dose, randomized, double-blind, placebo-controlled aller ( Bazelmans, D; Berkowitz, RB; Georges, G; Godfrey, P; Liao, Y; Lutz, C; McCafferty, F; Meeves, S, 2006) |
| "Pretreatment with fexofenadine 2 hours before immunotherapy significantly reduced the occurrence of severe SRs (P = ." | 2.72 | Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. ( Murata, K; Nakai, Y; Ohashi, Y, 2006) |
| "Mizolastine was associated with early phase reduction of: i) clinical symptoms (p < 0." | 2.71 | Mizolastine and fexofenadine modulate cytokine pattern after nasal allergen challenge. ( Ciprandi, G; Cirillo, I; Vizzaccaro, A, 2004) |
| " Patients (and investigators) reported any adverse events during the trial." | 2.71 | Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis--a pooled analysis of three studies. ( Bachert, C; Finn, AF; Hedlin, G; Meltzer, EO; Rosado Pinto, JE; Ruuth, E; Scheinmann, P; Wahn, U, 2004) |
| "Japanese cedar pollinosis, a common disease with morbidity of approximately 20% in the Japanese population, is characterized by subjectively irritating symptoms during an annual 3-month period." | 2.71 | The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen. ( Fujieda, S; Hyo, S; Kawada, R; Kitazawa, S; Takenaka, H, 2005) |
| " and adverse events were recorded in diary cards by the patients in form of scores as well as by the investigator at each visit." | 2.71 | The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis. ( Direkwattanachai, C; Ngamphaiboon, J; Tiensuwan, M; Vangveeravong, M; Visitsunthorn, N, 2005) |
| " There was no significant difference in adverse events between fexofenadine and placebo, either overall or by causality." | 2.71 | Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. ( Bachert, C; Baena-Cagnani, C; Decosta, P; Finn, AF; Hedlin, G; Kowalski, ML; Meltzer, EO; Potter, P; Rosado Pinto, JE; Ruuth, E; Scheinmann, P; Simons, FE; Wahn, U, 2003) |
| "Fexofenadine, 15, 30, and 60 mg twice daily, was safe and well tolerated in this large pediatric patient population." | 2.70 | Safety of fexofenadine in children treated for seasonal allergic rhinitis. ( Bernstein, DI; Goldsobel, A; Graft, DF; Long, J; Meltzer, EO; Portnoy, J, 2001) |
| " Incidence of treatment-related adverse events was 1." | 2.70 | Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. ( Berkowitz, RB; Lutz, C; Meeves, S; Moss, M; Weiler, J; Weiler, K; Woodworth, GG, 2002) |
| "Treatment with fexofenadine resulted in inhibition of allergen-induced symptoms and increased vascular permeability, but not the release of histamine and tryptase." | 2.70 | Effects of fexofenadine on the early response to nasal allergen challenge. ( Allocco, FT; Baroody, FM; deTineo, M; Naclerio, RM; Votypka, V, 2002) |
| "Fexofenadine was administered in daily doses of 120 or 240 mg, each in single and divided units given over 5 days." | 2.69 | Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance. ( O'Hanlon, JF; Vermeeren, A, 1998) |
| "Fexofenadine was as potent as terfenadine in limiting pruritus and nasal congestion." | 2.69 | Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen. ( Fellrath, JM; Rahm, F; Spertini, F; Terrien, MH, 1999) |
| "Antihistamines effectively treat seasonal allergic rhinitis (SAR), although the ability of this drug class to reduce nasal congestion is limited." | 2.69 | The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. ( Compton, D; Mason, J; Ricard, N; Stewart, J; Sussman, GL, 1999) |
| "Fexofenadine HCl has been investigated more extensively for possible electrophysiological effects than any other antihistamine." | 2.69 | Cardiovascular safety of fexofenadine HCl. ( Ahlbrandt, R; Brown, AM; Mason, J; Pratt, C; Rampe, D; Reynolds, R; Russell, T, 1999) |
| "Fexofenadine HCl (Allegra, Telfast) is approved in the US for twice-daily dosing for treatment of seasonal allergic rhinitis." | 2.69 | Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. ( Casale, TB; Meltzer, EO; Nathan, RA; Thompson, AK, 1999) |
| " Efficacy was maintained for the entire dosing interval (ie, for 24 hours)." | 2.69 | Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. ( Bousquet, J; Howarth, PH; Reynolds, R; Roi, L; Stern, MA, 1999) |
| " The incidence of adverse events was low and similar across all treatment groups." | 2.69 | Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. ( Juniper, EF; Van Cauwenberge, P, 2000) |
| " The frequency of adverse events was similar among fexofenadine HCl and placebo groups, with no dose-related trends." | 2.68 | Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. ( Ahlbrandt, R; Bernstein, DI; Mason, J; Nathan, RA; Schoenwetter, WF; Storms, W, 1997) |
| "Fexofenadine has been used for its efficacy and safety in the treatment of allergic rhinitis (AR) for many years although no meta-analyses supporting its use currently exist." | 2.47 | Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. ( Badellino, H; Baena-Cagnani, CE; Baena-Cagnani, R; Braido, F; Canonica, GW; Compalati, E; Gómez, RM; Penagos, M, 2011) |
| "Fexofenadine was associated with significantly lower nasal congestion scores compared with placebo in 4 studies (P <- 0." | 2.45 | A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. ( Bachert, C, 2009) |
| " No major cytochrome P450 inhibition has been reported with desloratadine, fexofenadine and levocetirizine, and the bioavailability of desloratadine is minimally affected by drugs interfering with transporter molecules." | 2.44 | Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. ( Devillier, P; Faisy, C; Roche, N, 2008) |
| " In addition, small tablet size and once-daily dosing may provide patients with increased convenience and improve adherence." | 2.43 | Once-daily immediate-release fexofenadine and sustained-release pseudoephedrine combination: a new treatment option for allergic rhinitis. ( Mansfield, LE, 2006) |
| "Fexofenadine has also been shown to have a favorable effect on nasal congestion." | 2.42 | Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. ( Appajosyula, S; Meeves, SG, 2003) |
| " Twelve-lead electrocardiographic data were collected once before and after dosing or serially throughout these studies." | 2.40 | Cardiovascular safety of fexofenadine HCl. ( Ahlbrandt, R; Mason, J; Pratt, CM; Reynolds, R; Russell, T, 1999) |
| "Patients with Japanese cedar pollinosis were treated orally with FEX twice a day at a single dose of 60 mg for two weeks during Japanese cedar pollen season (February 2011 to April 2011)." | 1.38 | Enhancement of clara cell 10-kD protein (CC10) production from nasal epithelial cells by fexofenadine hydrochloride. ( Asano, K; Furuta, A; Kanai, K; Kanei, A; Nogaki, T; Suzaki, H; Suzaki, I, 2012) |
| "CD14+ cells prepared from patients with pollinosis to Japanese cedar pollen were stimulated with specific allergen extracted from Japanese cedar pollen (Cry j 1) in the presence of azelastine (AZE), ketotifen (KET), fexofenadine (FEX) and oxatomide (OXA) for 6 days." | 1.37 | Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. ( Asano, K; Furuta, A; Hirano, K; Shoji, N; Suzaki, H, 2011) |
| "Olopatadine hydrochloride (olopatadine) is an antiallergic agent with histamine H(1) receptor antagonistic action." | 1.35 | Efficacy of repeated pretreatment with olopatadine hydrochloride on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats. ( Kimoto, N; Tamura, T, 2009) |
| " Second-generation antihistamines have become increasingly popular because of their comparable efficacy and lower incidence of adverse effects relative to their first-generation counterparts, and the safety and efficacy of this drug class are established in the adult population." | 1.35 | Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. ( Moeller, ML; Nahata, MC; Phan, H, 2009) |
| "Fexofenadine was administered once a day at a dose of 120 mg." | 1.35 | Effects of fexofenadine on inflammatory mediators in nasal lavage fluid in intermittent allergic rhinitis. ( Ewert, R; Gläser, S; Gustavus, B; Hanf, G; Koch, B; Kunkel, G; Noga, O; Schäper, C, 2009) |
| "The long QT syndrome is a rare disease." | 1.33 | Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs. ( Codreanu, A; de Chillou, C; Moneret-Vautrin, DA, 2006) |
| "Fexofenadine hydrochloride is a non-sedating antihistamine that is used in the treatment of symptoms associated with seasonal allergic rhinitis and chronic idiopathic urticaria." | 1.32 | The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride. ( Jensen, BK; Kittner, B; Krishna, R; Krishnaswami, S; Sankoh, AJ, 2004) |
| "PBL prepared from donors with pollinosis were cultured with either Japanese cedar pollen allergen, Cry j 1, or interleukin (IL)-4 in the presence of various doses of FEX for 6 days." | 1.32 | Suppressive activity of fexofenadine hydrochloride on thymus- and activation-regulated chemokine production from human peripheral blood leukocytes in response to antigenic stimulation in vitro. ( Asano, K; Kanai, K; Suzaki, H, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (12.66) | 18.2507 |
| 2000's | 57 (72.15) | 29.6817 |
| 2010's | 12 (15.19) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y | 1 |
| Ye, XJ | 1 |
| Zhao, CL | 1 |
| Ji, Q | 1 |
| Otsuka, H | 1 |
| Otsuka, K | 1 |
| Matsune, S | 1 |
| Okubo, K | 3 |
| Sawatsubashi, M | 1 |
| Gotoh, M | 2 |
| Asako, M | 1 |
| Nomura, Y | 1 |
| Togawa, M | 1 |
| Saito, A | 1 |
| Honda, T | 1 |
| Ohashi, Y | 2 |
| Izumi, N | 1 |
| Mizuguchi, H | 2 |
| Umehara, H | 1 |
| Ogino, S | 1 |
| Fukui, H | 2 |
| Takasaki, K | 1 |
| Enatsu, K | 1 |
| Kumagami, H | 1 |
| Takahashi, H | 1 |
| Sagara, H | 1 |
| Yukawa, T | 1 |
| Kashima, R | 1 |
| Okada, T | 1 |
| Fukuda, T | 1 |
| Bachert, C | 3 |
| Enomoto, T | 1 |
| Lu, HQ | 1 |
| Yin, M | 1 |
| Sakoda, T | 1 |
| Dake, Y | 1 |
| Enomoto, K | 1 |
| Ide, T | 1 |
| Cheng, L | 1 |
| Tamura, T | 1 |
| Kimoto, N | 1 |
| Horak, F | 2 |
| Zieglmayer, P | 1 |
| Zieglmayer, R | 2 |
| Lemell, P | 1 |
| Phan, H | 1 |
| Moeller, ML | 1 |
| Nahata, MC | 1 |
| Schäper, C | 1 |
| Gustavus, B | 1 |
| Koch, B | 1 |
| Ewert, R | 1 |
| Hanf, G | 1 |
| Kunkel, G | 1 |
| Noga, O | 1 |
| Gläser, S | 1 |
| Mösges, R | 2 |
| Lehmacher, W | 1 |
| Pasch, N | 1 |
| Vent, J | 1 |
| Shoji, N | 1 |
| Asano, K | 3 |
| Furuta, A | 2 |
| Hirano, K | 1 |
| Suzaki, H | 3 |
| Compalati, E | 1 |
| Baena-Cagnani, R | 1 |
| Penagos, M | 1 |
| Badellino, H | 1 |
| Braido, F | 1 |
| Gómez, RM | 1 |
| Canonica, GW | 1 |
| Baena-Cagnani, CE | 1 |
| Kamei, H | 1 |
| Isaji, A | 1 |
| Noda, Y | 1 |
| Ishikawa, K | 1 |
| Senzaki, K | 1 |
| Yamada, K | 1 |
| Sugiura, K | 1 |
| Tomita, Y | 1 |
| Nabeshima, T | 1 |
| Takahashi, G | 1 |
| Matsuzaki, Z | 1 |
| Okamoto, A | 1 |
| Ito, E | 1 |
| Matsuoka, T | 1 |
| Nakayama, T | 1 |
| Masuyama, K | 1 |
| Stokes, JR | 1 |
| Romero, FA | 1 |
| Allan, RJ | 1 |
| Phillips, PG | 1 |
| Hackman, F | 1 |
| Misfeldt, J | 1 |
| Casale, TB | 2 |
| Kitamura, Y | 1 |
| Ogishi, H | 1 |
| Kuroda, W | 1 |
| Hattori, M | 1 |
| Takeda, N | 1 |
| Nogaki, T | 1 |
| Kanai, K | 2 |
| Suzaki, I | 1 |
| Kanei, A | 1 |
| Berkowitz, RB | 2 |
| Woodworth, GG | 2 |
| Lutz, C | 2 |
| Weiler, K | 1 |
| Weiler, J | 1 |
| Moss, M | 1 |
| Meeves, S | 3 |
| Wilson, AM | 2 |
| Haggart, K | 1 |
| Sims, EJ | 2 |
| Lipworth, BJ | 3 |
| Koop, A | 1 |
| Mohler, SR | 1 |
| Nicholson, A | 1 |
| Harvey, P | 1 |
| Miura, Y | 1 |
| Meeves, SG | 2 |
| Allocco, FT | 1 |
| Votypka, V | 1 |
| deTineo, M | 2 |
| Naclerio, RM | 2 |
| Baroody, FM | 2 |
| Miyabe, S | 1 |
| Koizuka, I | 1 |
| Ochi, K | 1 |
| Tanaka, K | 1 |
| Kuroda, H | 1 |
| Takatsu, M | 1 |
| Kinoshita, H | 1 |
| Sugiyama, Y | 1 |
| Lee, DK | 1 |
| Jackson, CM | 1 |
| Wahn, U | 2 |
| Meltzer, EO | 4 |
| Finn, AF | 2 |
| Kowalski, ML | 1 |
| Decosta, P | 1 |
| Hedlin, G | 2 |
| Scheinmann, P | 2 |
| Rosado Pinto, JE | 2 |
| Baena-Cagnani, C | 1 |
| Potter, P | 1 |
| Simons, FE | 1 |
| Ruuth, E | 2 |
| Glass, DJ | 1 |
| Harper, AS | 1 |
| Appajosyula, S | 1 |
| Portnoy, JM | 1 |
| Simon, SD | 1 |
| Hampel, F | 1 |
| Ratner, P | 1 |
| Mansfield, L | 1 |
| Liao, Y | 2 |
| Georges, G | 2 |
| Moinuddin, R | 1 |
| Maleckar, B | 1 |
| Ciprandi, G | 1 |
| Cirillo, I | 1 |
| Vizzaccaro, A | 1 |
| LaForce, CF | 1 |
| Corren, J | 1 |
| Wheeler, WJ | 1 |
| Berger, WE | 1 |
| Krishna, R | 1 |
| Krishnaswami, S | 1 |
| Kittner, B | 2 |
| Sankoh, AJ | 1 |
| Jensen, BK | 1 |
| Shimada, K | 1 |
| Ritsu, M | 1 |
| Okuda, M | 1 |
| Crawford, B | 1 |
| Hyo, S | 1 |
| Fujieda, S | 1 |
| Kawada, R | 1 |
| Kitazawa, S | 1 |
| Takenaka, H | 1 |
| Conboy-Ellis, K | 1 |
| Green, GR | 1 |
| Górska-Ciebiada, M | 1 |
| Ciebiada, M | 1 |
| Zakrzewska, A | 1 |
| Górski, P | 1 |
| Grzelewska-Rzymowska, I | 1 |
| Ngamphaiboon, J | 1 |
| Direkwattanachai, C | 1 |
| Visitsunthorn, N | 1 |
| Vangveeravong, M | 1 |
| Tiensuwan, M | 1 |
| Mansfield, LE | 2 |
| Nakai, Y | 1 |
| Murata, K | 1 |
| Spangler, DL | 1 |
| Brunton, S | 1 |
| McCafferty, F | 1 |
| Bazelmans, D | 1 |
| Godfrey, P | 1 |
| Lehman, JM | 1 |
| Blaiss, MS | 1 |
| Moneret-Vautrin, DA | 1 |
| de Chillou, C | 1 |
| Codreanu, A | 1 |
| Gamzatova, AA | 1 |
| Gadzhimirzaev, GA | 1 |
| Abusuev, SA | 1 |
| Gamzatova, EG | 1 |
| Milgrom, H | 1 |
| Lanier, R | 1 |
| Hampel, FC | 1 |
| Devillier, P | 1 |
| Roche, N | 1 |
| Faisy, C | 1 |
| De Vos, C | 2 |
| Mitchev, K | 1 |
| Pinelli, ME | 1 |
| Derde, MP | 1 |
| Boev, R | 1 |
| Bernstein, DI | 2 |
| Schoenwetter, WF | 1 |
| Nathan, RA | 2 |
| Storms, W | 1 |
| Ahlbrandt, R | 3 |
| Mason, J | 4 |
| Markham, A | 1 |
| Wagstaff, AJ | 1 |
| Vermeeren, A | 1 |
| O'Hanlon, JF | 1 |
| Abdelaziz, MM | 1 |
| Devalia, JL | 1 |
| Khair, OA | 1 |
| Bayram, H | 1 |
| Prior, AJ | 1 |
| Davies, RJ | 1 |
| Pratt, CM | 1 |
| Russell, T | 2 |
| Reynolds, R | 3 |
| Terrien, MH | 1 |
| Rahm, F | 1 |
| Fellrath, JM | 1 |
| Spertini, F | 1 |
| Sussman, GL | 1 |
| Compton, D | 1 |
| Stewart, J | 1 |
| Ricard, N | 1 |
| Pratt, C | 1 |
| Brown, AM | 1 |
| Rampe, D | 1 |
| Thompson, AK | 1 |
| Howarth, PH | 1 |
| Stern, MA | 1 |
| Roi, L | 1 |
| Bousquet, J | 1 |
| Weiler, JM | 1 |
| Bloomfield, JR | 1 |
| Grant, AR | 1 |
| Layton, TA | 1 |
| Brown, TL | 1 |
| McKenzie, DR | 1 |
| Baker, TW | 1 |
| Watson, GS | 1 |
| Simpson, K | 1 |
| Jarvis, B | 1 |
| Van Cauwenberge, P | 1 |
| Juniper, EF | 1 |
| Prenner, BM | 1 |
| Capano, D | 1 |
| Harris, AG | 1 |
| Shaikh, WA | 1 |
| Amichai, B | 1 |
| Grunwald, MH | 1 |
| Brenner, L | 1 |
| Stübner, P | 1 |
| Kavina, A | 1 |
| Burtin, B | 1 |
| Donnelly, F | 1 |
| Graft, DF | 1 |
| Goldsobel, A | 1 |
| Portnoy, J | 1 |
| Long, J | 1 |
| Orr, LC | 1 |
| Coutie, WJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, 4 Way Cross-over, Placebo Controlled Trial to Evaluate the Onset of Action of Bilastine 20 mg vs. Placebo, Cetirizine 10 mg, and Fexofenadine 120 mg in the Vienna Challenge Chamber[NCT00420082] | Phase 2 | 75 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Multicentre, International, Adaptive, Open-label, Repeated Administration Pharmacokinetic Study of Bilastine in Children From 2 to <12 Years of Age With Allergic Rhinoconjunctivitis or Chronic Urticaria[NCT01081574] | Phase 1/Phase 2 | 36 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age[NCT04957927] | Phase 4 | 60 participants (Anticipated) | Interventional | 2020-12-12 | Recruiting | ||
| The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015] | Phase 4 | 102 participants (Actual) | Interventional | 2005-07-31 | Terminated (stopped due to Difficulty in recruitment) | ||
| Nasal Ocular Reflexes Contribute to Eye Symptoms in Patients With Allergic Rhinitis[NCT00117832] | 20 participants | Interventional | 2005-03-31 | Completed | |||
| Quality of Life in Patients With Allergic Rhinitis: a Clinical Trial Comparing the Use of Bilastine Versus Loratadine[NCT02513290] | Phase 4 | 73 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.24 |
| Fluticasone Propionate + Placebo | -0.14 |
"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.52 |
| Fluticasone Propionate + Placebo | -0.29 |
"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.22 |
| Fluticasone Propionate + Placebo | -0.25 |
"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.41 |
| Fluticasone Propionate + Placebo | -0.47 |
"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -1.66 |
| Fluticasone Propionate + Placebo | -2.21 |
13 reviews available for fexofenadine and Hay Fever
| Article | Year |
|---|---|
[Clinical Management of Japanese Cedar Pollinosis].
Topics: Administration, Inhalation; Cedrus; Desensitization, Immunologic; Disorders of Excessive Somnolence; | 2016 |
A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cetirizine; Child; Clinical Trials as Topic; Female; His | 2009 |
Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials.
Topics: Adult; Child, Preschool; Double-Blind Method; Histamine H1 Antagonists, Non-Sedating; Humans; Random | 2011 |
Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment.
Topics: Anti-Allergic Agents; Histamine H1 Antagonists; Humans; Rhinitis, Allergic, Seasonal; Terfenadine; T | 2003 |
Management of seasonal allergic rhinitis: comparative efficacy of the newer-generation prescription antihistamines.
Topics: Adolescent; Adult; Cetirizine; Child; Child, Preschool; Histamine H1 Antagonists; Histamine H1 Antag | 2005 |
Once-daily immediate-release fexofenadine and sustained-release pseudoephedrine combination: a new treatment option for allergic rhinitis.
Topics: Animals; Delayed-Action Preparations; Drug Therapy, Combination; Ephedrine; Humans; Rhinitis, Allerg | 2006 |
Efficacy and central nervous system impairment of newer-generation prescription antihistamines in seasonal allergic rhinitis.
Topics: Central Nervous System; Cetirizine; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating | 2006 |
Selecting the optimal oral antihistamine for patients with allergic rhinitis.
Topics: Administration, Oral; Cardiovascular System; Central Nervous System; Cetirizine; Drug Interactions; | 2006 |
Fexofenadine in pediatrics: oral tablet and suspension formulations.
Topics: Administration, Oral; Animals; Chemistry, Pharmaceutical; Child; Child, Preschool; Deglutition; Huma | 2008 |
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.
Topics: Cetirizine; Drug Interactions; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Rhinitis, | 2008 |
Fexofenadine.
Topics: Animals; Histamine Antagonists; Humans; Rhinitis, Allergic, Seasonal; Terfenadine; Urticaria | 1998 |
Cardiovascular safety of fexofenadine HCl.
Topics: Double-Blind Method; Drug Interactions; Electrocardiography; Heart Conduction System; Histamine Anta | 1999 |
Fexofenadine hydrochloride--a new anti-histaminic drug.
Topics: Chronic Disease; Clinical Trials as Topic; Drug Interactions; Histamine H1 Antagonists; Humans; Pati | 2001 |
42 trials available for fexofenadine and Hay Fever
| Article | Year |
|---|---|
[The effect of combined therapy on seasonal allergic rhinitis].
Topics: Administration, Intranasal; Budesonide; Double-Blind Method; Glucocorticoids; Humans; Leukotriene An | 2016 |
Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study.
Topics: Adult; Asian People; Benzimidazoles; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; | 2017 |
Relationship between airborne pollen count and treatment outcome in Japanese cedar pollinosis patients.
Topics: Adult; Air; Anti-Allergic Agents; Anti-Inflammatory Agents; Cryptomeria; Female; Humans; Male; Polle | 2009 |
Effects of pranlukast hydrate on airway hyperresponsiveness in non-asthmatic patients with Japanese cedar pollinosis.
Topics: Acetylcholine; Activities of Daily Living; Adult; Anti-Allergic Agents; Anti-Asthmatic Agents; Antig | 2009 |
Evaluation of the efficacy and safety of olopatadine and fexofenadine compared with placebo in Japanese cedar pollinosis using an environmental exposure unit.
Topics: Adult; Allergens; Cryptomeria; Dibenzoxepins; Double-Blind Method; Female; Follow-Up Studies; Histam | 2009 |
The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber.
Topics: Adolescent; Adult; Allergens; Anti-Allergic Agents; Benzimidazoles; Cetirizine; Cross-Over Studies; | 2010 |
The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber.
Topics: Adolescent; Adult; Allergens; Anti-Allergic Agents; Benzimidazoles; Cetirizine; Cross-Over Studies; | 2010 |
The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber.
Topics: Adolescent; Adult; Allergens; Anti-Allergic Agents; Benzimidazoles; Cetirizine; Cross-Over Studies; | 2010 |
The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber.
Topics: Adolescent; Adult; Allergens; Anti-Allergic Agents; Benzimidazoles; Cetirizine; Cross-Over Studies; | 2010 |
Assessment of the antiobstructive effect of fexofenadine on nasal allergy challenge in patients with seasonal allergic rhinitis.
Topics: Administration, Oral; Antigens, Plant; Double-Blind Method; Histamine H1 Antagonists, Non-Sedating; | 2009 |
Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers.
Topics: Adolescent; Dibenzoxepins; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Male; Olop | 2012 |
A randomized control trail of stepwise treatment with fluticasone propionate nasal spray and fexofenadine hydrochloride tablet for seasonal allergic rhinitis.
Topics: Adult; Androstadienes; Anti-Allergic Agents; Female; Fluticasone; Humans; Male; Middle Aged; Nasal S | 2012 |
The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms.
Topics: Adult; Ambrosia; Anti-Allergic Agents; Cross-Over Studies; Cyclobutanes; Double-Blind Method; Drug C | 2012 |
Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit.
Topics: Adolescent; Adult; Aged; Child; Double-Blind Method; Drug Therapy, Combination; Ephedrine; Female; H | 2002 |
Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis.
Topics: Adult; Air Pollutants; Allergens; Cross-Over Studies; Double-Blind Method; Environmental Exposure; F | 2002 |
The use of handheld computers in clinical trials.
Topics: Adult; Anti-Allergic Agents; Data Collection; Databases, Factual; Double-Blind Method; Humans; Mathe | 2002 |
Effects of fexofenadine on the early response to nasal allergen challenge.
Topics: Adolescent; Adult; Allergens; Biomarkers; Capillary Permeability; Cross-Over Studies; Double-Blind M | 2002 |
Effect of fexofenadine hydrochloride on cedar pollinosis.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Cedrus; Drug Administration Schedule; Female; Histami | 2003 |
Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis.
Topics: Anti-Allergic Agents; Child; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Male; Rh | 2003 |
Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Cetirizine; Child; Double-Blind Method; Female; Human | 2003 |
Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis.
Topics: Acetates; Adolescent; Adult; Ambrosia; Anti-Allergic Agents; Cyclopropanes; Double-Blind Method; Dru | 2004 |
Mizolastine and fexofenadine modulate cytokine pattern after nasal allergen challenge.
Topics: Adult; Allergens; Anti-Allergic Agents; Benzimidazoles; Conjunctivitis, Allergic; Cytokines; Double- | 2004 |
Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis--a pooled analysis of three studies.
Topics: Anti-Allergic Agents; Child; Double-Blind Method; Female; Headache; Histamine H1 Antagonists; Humans | 2004 |
Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Double-Blind Method; Drug Therapy, Combination; F | 2004 |
Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season.
Topics: Adult; Allergens; Cryptomeria; Double-Blind Method; Efficiency; Female; Histamine H1 Antagonists; Hu | 2005 |
The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen.
Topics: Adult; Cetirizine; Cryptomeria; Double-Blind Method; Drug Administration Schedule; Female; Histamine | 2005 |
[Serum sICAM-1 in patients suffering from allergic rhinitis treated with fexofenadine or fluticasone].
Topics: Adolescent; Adult; Androstadienes; Anti-Allergic Agents; Female; Fluticasone; Humans; Intercellular | 2004 |
The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis.
Topics: Anti-Allergic Agents; Asian People; Child; Female; Histamine H1 Antagonists; Humans; Male; Multicent | 2005 |
Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis.
Topics: Adult; Anti-Allergic Agents; Cedrus; Dermatophagoides farinae; Desensitization, Immunologic; Female; | 2006 |
Onset of action of fexofenadine hydrochloride 60 mg/pseudoephedrine hydrochloride 120 mg in subjects aged 12 years with moderate to severe seasonal allergic rhinitis: a pooled analysis of two single-dose, randomized, double-blind, placebo-controlled aller
Topics: Adult; Allergens; Anti-Allergic Agents; Demography; Double-Blind Method; Ephedrine; Female; Humans; | 2006 |
Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old.
Topics: Age Factors; Anti-Allergic Agents; Body Temperature; Child, Preschool; Cough; Double-Blind Method; E | 2007 |
Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Child; Drug Evaluation; Female; Histamine Antagonists; Humans; Male; Middle | 1997 |
Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance.
Topics: Adult; Alcohol Drinking; Anti-Allergic Agents; Automobile Driving; Clemastine; Cross-Over Studies; D | 1998 |
Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen.
Topics: Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ma | 1999 |
The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Child; Delayed-Action Preparations; Double-Blind | 1999 |
Cardiovascular safety of fexofenadine HCl.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Electrocardiography; Hista | 1999 |
Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis.
Topics: Activities of Daily Living; Adolescent; Aged; Anti-Allergic Agents; Child; Double-Blind Method; Drug | 1999 |
Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Cetirizine; Child; Double-Blind Method; Drug Administ | 1999 |
Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator.
Topics: Adult; Automobile Driving; Cross-Over Studies; Diphenhydramine; Double-Blind Method; Ethanol; Female | 2000 |
Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Child; Double-Blind Method; Drug Administration Schedule; Female; Histamine H1 An | 2000 |
Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Child; Double-Blind Method; Drug Administration Schedule; Female; Histamine H1 An | 2000 |
Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Child; Double-Blind Method; Drug Administration Schedule; Female; Histamine H1 An | 2000 |
Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Child; Double-Blind Method; Drug Administration Schedule; Female; Histamine H1 An | 2000 |
Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: a double-blind comparison with crossover treatment of nonresponders.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Cross-Over Studies; Double-Blind Method; Femal | 2000 |
The changing face of antihistamines and cardiac adverse drug reactions: a clinical perspective.
Topics: Cardiovascular Diseases; Drug Interactions; Electrocardiography; Erythromycin; Female; Histamine H1 | 2000 |
Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis.
Topics: Adult; Anti-Allergic Agents; Bronchial Provocation Tests; Cetirizine; Cross-Over Studies; Double-Bli | 2001 |
Safety of fexofenadine in children treated for seasonal allergic rhinitis.
Topics: Asthma; Child; Double-Blind Method; Humans; Rhinitis, Allergic, Seasonal; Terfenadine; Therapeutic E | 2001 |
A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis.
Topics: Acetates; Adult; Anti-Allergic Agents; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Drug | 2002 |
24 other studies available for fexofenadine and Hay Fever
| Article | Year |
|---|---|
Nasal Symptoms Reduction and Decreased Neutrophilia in Japanese Cedar Pollinosis With Prophylactic Treatment With a Combination of Montelukast, Fexofenadine, and Fluticasone Nasal Spray.
Topics: Acetates; Adult; Anti-Allergic Agents; Cetirizine; Cryptomeria; Cyclopropanes; Drug Therapy, Combina | 2019 |
Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asthma; Butyrophenones; Cetirizine; Child; Chlorpheniram | 2008 |
Efficacy of repeated pretreatment with olopatadine hydrochloride on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats.
Topics: Administration, Intranasal; Animals; Anti-Allergic Agents; Dibenzoxepins; Disease Models, Animal; Dr | 2009 |
Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast.
Topics: Acetates; Administration, Oral; Adult; Anti-Allergic Agents; Anti-Asthmatic Agents; Astemizole; Ceti | 2009 |
Effects of fexofenadine on inflammatory mediators in nasal lavage fluid in intermittent allergic rhinitis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antigens, Plant; Artemisia; Betula; Disease Progression; Eosi | 2009 |
Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro.
Topics: Adult; Antigens, Plant; Cell Proliferation; Chemokine CCL17; Chemokine CCL22; Chlorpheniramine; Extr | 2011 |
Preseasonal prophylactic treatment with antihistamines suppresses IL-5 but not IL-33 mRNA expression in the nasal mucosa of patients with seasonal allergic rhinitis caused by Japanese cedar pollen.
Topics: Butyrophenones; Cryptomeria; Female; Histamine Antagonists; Humans; Interleukin-33; Interleukin-5; I | 2012 |
Enhancement of clara cell 10-kD protein (CC10) production from nasal epithelial cells by fexofenadine hydrochloride.
Topics: Adult; Cells, Cultured; Cryptomeria; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Histamine | 2012 |
The use of antihistamines in safety-critical jobs: a meeting report.
Topics: Aviation; Cognition; Histamine H1 Antagonists; Humans; Occupational Diseases; Occupations; Rhinitis, | 2002 |
Decongestant effects of antihistamines: a class effect?
Topics: Controlled Clinical Trials as Topic; Histamine H1 Antagonists; Humans; Loratadine; Nasal Decongestan | 2003 |
Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine.
Topics: Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Patient Satisf | 2003 |
Is 3-mm less drowsiness important?
Topics: Anti-Allergic Agents; Automobile Driving; Cetirizine; Humans; Rhinitis, Allergic, Seasonal; Severity | 2003 |
Suppressive activity of fexofenadine hydrochloride on thymus- and activation-regulated chemokine production from human peripheral blood leukocytes in response to antigenic stimulation in vitro.
Topics: Adult; Allergens; Antigens, Plant; Cell Division; Chemokine CCL17; Chemokines, CC; Dose-Response Rel | 2004 |
The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride.
Topics: Administration, Oral; Adult; Age Factors; Analysis of Variance; Body Weight; Child; Child, Preschool | 2004 |
Treatment of ear pain in pilots in flight.
Topics: Aerospace Medicine; Anti-Allergic Agents; Humans; Loratadine; Pain; Rhinitis, Allergic, Seasonal; St | 2005 |
Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs.
Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Asthmatic Agents; Butyrophenones; Cetirizine; Conjunct | 2006 |
[Treatment of allergic rhinitis associated with hypothyroidism].
Topics: Adult; Anti-Allergic Agents; Female; Humans; Hypothyroidism; Immunoglobulins; Male; Middle Aged; Rhi | 2006 |
Non-interventional study comparing treatment satisfaction in patients treated with antihistamines.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Cetirizine; Child; | 2008 |
Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis.
Topics: Cell Adhesion; Cell Membrane Permeability; Cells, Cultured; Chemokine CCL5; Chemotaxis, Leukocyte; C | 1998 |
Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria.
Topics: Administration, Oral; Adolescent; Adult; Anti-Allergic Agents; Chronic Disease; Dose-Response Relati | 2000 |
[Multiple prevention. On the way to an ideal antihistamine?].
Topics: Histamine H1 Antagonists; Humans; Mast Cells; Rhinitis, Allergic, Seasonal; Terfenadine; Treatment O | 2000 |
Newer antihistamines.
Topics: Administration, Oral; Anti-Allergic Agents; Cetirizine; Chlorpheniramine; Conscious Sedation; Diphen | 2001 |
[Seasonal allergic rhinitis. Nasal obstruction can also beh improved].
Topics: Anti-Allergic Agents; Double-Blind Method; Humans; Loratadine; Multicenter Studies as Topic; Nasal O | 2001 |
[Hay fever and asthma. Many of your patients have both].
Topics: Asthma; Histamine H1 Antagonists; Humans; Rhinitis, Allergic, Seasonal; Terfenadine; Treatment Outco | 2002 |